Average ibogaine treatment cost?

Ibogaine programs typically range from $6,000 to $25,000, depending on medical infrastructure, program length, and accommodations. A short single-session flood dose at a minimally staffed clinic sits at the low end; a multi-week program at a licensed facility with continuous cardiac monitoring, on-site physicians, and structured aftercare sits at the high end.

Why more expensive than ayahuasca?

Ibogaine carries meaningful cardiac risk (QT prolongation) that requires ECG screening, echocardiogram in higher-risk cases, continuous telemetry, and physician staffing. That clinical infrastructure is expensive to operate and is the single largest reason ibogaine programs cost more than plant-medicine ceremonies without a comparable cardiac risk profile.

Is ibogaine covered by insurance?

In almost all cases, no. Ibogaine is Schedule I in the US and is not FDA-approved, so US insurance carriers do not reimburse it. It is legally administered outside the US in specific jurisdictions. Some families use HSA/FSA funds for adjacent medical costs but not for ibogaine itself.

What should be included in the price?

Pre-arrival cardiac screening (ECG, sometimes echocardiogram), full metabolic and liver bloodwork, a medically supervised medication taper if applicable, continuous cardiac telemetry, on-site physician presence, accommodations, meals, and structured post-treatment integration. If any of those are add-ons, the quoted price is incomplete.

Are cheaper ibogaine clinics safe?

Cheaper clinics are cheaper because they cut staffing hours, skip cardiac imaging, or run treatment in non-clinical settings. Ibogaine deaths in the medical literature are overwhelmingly associated with inadequate cardiac screening and unmonitored dosing. The savings on a lower-cost provider translate directly into a higher probability of an avoidable adverse cardiac event.

Cost of ibogaine treatment in Mexico?

Ibogaine treatment in Mexico typically ranges from $6,000 to $10,000 at basic clinics and $15,000 to $30,000 at licensed luxury facilities with full medical infrastructure. Mexico is one of the few countries where ibogaine can be legally administered in a clinical setting. The price gap reflects real differences in physician credentials, cardiac monitoring, accommodations, program length, and integration support.

What's included at a licensed clinic?

A complete program price should include airport transfers, private accommodations, organic meals, pre-arrival medical intake and cardiac clearance, the ibogaine dosing session with continuous telemetry, on-site physician and nursing coverage, IV hydration and magnesium support, adjunctive therapies (NAD+, vitamin drips, bodywork), and structured post-treatment integration.

How long does a program last?

Program length ranges from 3 to 5 days for a single flood-dose protocol at a basic clinic, up to 4 to 12 weeks at a licensed luxury facility offering comprehensive recovery. For opioid dependence, benzodiazepine tapering, or long-term addiction, clinical outcomes strongly favor programs of at least 2 to 4 weeks that include stabilization, the ibogaine window, and integration.

Is financing available?

Most licensed ibogaine clinics accept credit cards, wire transfers, and cryptocurrency, and many work with medical financing companies such as CareCredit, Prosper Healthcare Lending, or United Medical Credit for US residents. HSA and FSA funds generally cannot be applied to ibogaine itself but can sometimes cover ancillary medical services.

Ibogaine Treatment Cost | Sanctuary Tulum

Ibogaine treatment pricing sits in a range that surprises most people the first time they see it — commonly $6,000 to $25,000 for a program. The wide spread is not arbitrary. It reflects specific, quantifiable differences in cardiac screening, physician staffing, program length, and aftercare. Understanding what actually drives cost is the difference between paying for real clinical infrastructure and paying for marketing on top of an under-resourced clinic.

Why Ibogaine Costs More Than Other Plant Medicines

Ibogaine is pharmacologically different from ayahuasca or psilocybin in a way that matters for pricing. It prolongs the cardiac QT interval, which means every dose has to be preceded by a real cardiac workup and monitored throughout the treatment window. That workup and monitoring is where a large fraction of the cost of a legitimate program lives. See our detailed piece on ibogaine cardiac safety screening for the specific protocol.

The Four Main Cost Drivers

1. Cardiac Screening Infrastructure

A safe protocol requires, at minimum, a recent 12-lead ECG with QTc measurement; an echocardiogram is required for anyone with a cardiac history, family history of arrhythmia, or QTc at the upper end of normal. Metabolic and liver panels, electrolyte assessment (particularly potassium and magnesium), and a full medication review are non-optional inputs. Continuous cardiac telemetry through the treatment window requires on-site monitoring equipment and a clinician who can interpret it in real time. Clinics that price aggressively usually cut here first — often silently — because the equipment and staffing costs are large and largely invisible to the guest.

2. Physician Staffing Level

"On-call" and "on-site" are not the same and cost dramatically different amounts to staff. A physician who is physically present during the treatment window is available in seconds if a cardiac event develops; an on-call physician is a phone call and a drive away. Emergency-medicine-level staffing costs a facility meaningfully more than a general-practitioner-on-call arrangement, and this shows up in the treatment price. Ask any clinic specifically who is present at what times and what their credentials are — vague answers here are the single most reliable red flag.

3. Program Length

A single flood-dose session is a fundamentally different clinical product from a two- to four-week program that includes pre-treatment stabilization, the ibogaine window itself, a recovery period with follow-up bloodwork, and structured integration. Longer programs cost more because they occupy staff time and beds for longer, not because they are inherently better. For someone with a long opioid history or benzodiazepine use, the longer program is often the safer clinical decision because tapering, medical stabilization, and post-treatment support meaningfully reduce relapse risk.

4. Aftercare and Integration

Ibogaine's outcome data is significantly better in programs that include structured aftercare. That aftercare — integration counseling, medical follow-up, and often adjunctive modalities like ibogaine treatment integration or 5-MeO-DMT ceremonies in the days after ibogaine — requires staff time and space. Programs that quote a low price by removing aftercare are quoting for the acute treatment event only, not for the intervention that produces durable results. Ibogaine without integration disappoints far more often than ibogaine with integration does.

Broad Price Ranges

Bare-clinical single session ($4,000–$8,000): One flood dose, basic ECG, limited or no on-site physician, minimal aftercare. Widely available and where most preventable adverse events occur.
Mid-tier medical programs ($8,000–$15,000): Multi-day stay, more thorough screening, physician available on-site during dosing, some post-treatment integration.
Licensed multi-week programs ($15,000–$30,000+): Full cardiac workup including echocardiogram when indicated, continuous telemetry, on-site physician during treatment window, adjunctive therapies, and 2–8 weeks of structured integration.

Why the Cheap End Is Where the Risk Lives

Ibogaine has real cardiac risk. Fatalities documented in the peer-reviewed literature cluster in unsupervised or minimally supervised settings — hotel rooms, private homes, clinics without telemetry, or facilities that skipped ECG. The medicine itself is not what makes ibogaine dangerous; the absence of cardiac screening and monitoring is.¹ See the mechanism of action deep-dive for the pharmacology behind the cardiac effect. Choosing a lower-cost provider means, in practice, accepting a higher probability of an event that a well-staffed clinic would have caught earlier.

Cost vs. Alternatives

For families weighing ibogaine cost against repeated conventional treatment, the arithmetic is worth doing honestly. A single 30-day stay at a US residential treatment center commonly costs $30,000–$80,000. Multiple stays over years of relapse frequently exceed six figures in total. Ibogaine is not a guaranteed intervention and is not appropriate for everyone — but for the subset of people it is clinically appropriate for, a single well-run program often costs less than one conventional cycle of relapse and retreatment. The peer-reviewed ibogaine opioid addiction research² is the honest place to calibrate expectations before making that comparison.

What to Ask Before You Book

Ask specifically: What is the ECG and echocardiogram protocol? Who reviews the ECG and what QTc threshold do you use to exclude candidates? Is a physician physically present during the treatment window, and what are their credentials? What continuous monitoring is used? What is the emergency plan and the nearest hospital transfer time? What is included in aftercare and for how long? Any facility unwilling or unable to answer those in writing is one to avoid regardless of price. Our overview of a safe psychedelic facility covers the broader checklist.

Sanctuary Tulum's Approach

Sanctuary Tulum operates under a federal health license as a hospital and clinic. Ibogaine programs include pre-arrival ECG (with echocardiogram when indicated), on-site physician supervision throughout the treatment window, continuous cardiac telemetry, and multi-week integration.³ Pricing reflects those inputs. The full ibogaine treatment program page details what each package includes.

Psychedelic Retreats Wellness Center at Sanctuary Tulum — oceanfront luxury accommodations with all-inclusive medically licensed supervised psychedelic ceremonies — Psychedelic Retreats & Wellness Center at Sanctuary Tulum

Ibogaine Treatment Cost in Mexico vs. Other Jurisdictions

Mexico is one of the few jurisdictions where ibogaine treatment can be legally administered in a licensed clinical setting, which is why the majority of high-volume, medically supervised ibogaine programs operate there. Costs in Mexico typically undercut equivalent programs in Costa Rica, Portugal, and New Zealand by 20–40% — not because clinical standards are lower, but because operational overhead (staffing, real estate, imports) is meaningfully lower. The pricing gap between a Mexican licensed facility and a Mexican unlicensed clinic is far wider than the pricing gap between comparable licensed facilities across countries. For a US or Canadian family evaluating ibogaine treatment in Mexico, the honest comparison is not Mexico vs. elsewhere — it is licensed medical infrastructure vs. unlicensed retreat, in whichever jurisdiction you are considering. See our ibogaine clinics in Mexico guide for jurisdiction-specific licensing details.

Bottom Line

Ibogaine treatment cost is not a marketing number — it is a proxy for cardiac screening depth, physician staffing hours, program length, and aftercare bandwidth. Normalize what is actually included, ask specifically about the cardiac protocol, and evaluate on clinical infrastructure rather than website design. The savings from a cheap provider are real; the medical risk they represent is also real. For the complete clinical overview, see our ibogaine treatment page.

References

Alper, K. R., Stajić, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57(2), 398–412. PubMed 22268458
Brown, T. K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36. PubMed 28643969
Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 9, 529. PubMed 29922156